Board of Directors

Board of Directors

Gisela Sitbon

Born 1958
Board member since 2012, Chairperson since 2014

Chairperson of the board, chairperson of the remuneration committee

Education and training:

Doctorate in medical sciences from the Karolinska Institute in Solna

Main experience:

Twenty-five years of experience in the life science industry, of which just over ten years in senior positions (including CEO) at Professional Genetics Laboratory AB and five years as head of section at Karo Bio AB. Business coach in the life science sector at STING AB and responsible for business development for growth companies at her own company ZENZ AB.

Other board appointments:

Active as business coach within the life science sector. Chairman of the Board of Beactica Therapeutics AB, Enginzyme AB and Gradientech AB. Board member of Annexin Pharmaceuticals AB, CollaboDoc AB, Encare AB, In Singulo AB, and Sitbon Bioscience Partner Zenz AB.

Holdings:

Holds 20,000 shares through the company Sitbon Bioscience Partner Zenz AB and 75,000 options.

Independent in relation to company and company management: Yes

Independent in relation to primary owners: Yes

Mattias Bengtsson

Born 1969
Board member since 2019

Member of the audit committee

EDUCATION AND TRAINING:

Master of Science in Chemical Engineering at Chalmers University of Technology in Gothenburg,  MBA at University of Gothenburg School of Business

MAIN EXPERIENCE:

More than 15 years of experience from AkzoNobel Pulp and Performance Chemicals AB, as General Manager Kromasil and Fine Chemicals, Manager Global Sales and Marketing, Manufacturing Manager and Product Category Manager. Currently CEO of Biolin Scientific AB.

OTHER BOARD APPOINTMENTS:

CEO and board member of Biolin Scientific AB. Board member of MaBeRo Consulting AB.

Holdings:

Holds 13,000 shares and 55,000 options.

Independent in relation to company and company management: Yes

Independent in relation to primary owners: Yes

Eva Byröd

Born 1952
Board member since 2017

EDUCATION AND TRAINING:

Master of Science in Chemical Engineering Chalmers University of Technology

MAIN EXPERIENCE:

More than twenty-five years of experience as a line manager in pharmaceutical research and development and ten years’ experience as a Project Manager/Project Director, working in early as well as late phase pharmaceutical development projects.                                                                                          

OTHER BOARD APPOINTMENTS:

Board member of Eva Byröd Consulting AB and deputy board member of Bo Karlberg Arkitektur & Utveckling AB.

HOLDINGS:

Holds 55,000 options.

Independent in relation to company and company management: Yes

Independent in relation to primary owners: Yes

Thomas Eldered

Born 1960
Board member since 2021

Education and training:

Master of Science in Industrial Economics, Linköpings tekniska högskola

Main experience:

Co-founder of Recipharm AB where Thomas was also the CEO between 2008–2021. Before that, Thomas was the Vice President for Recip AB and Factory Manager at Pharmacia. Numerous board appointments in companies primarily within the life science sector.                                                                                  

Other board appointments:

Chairman of the board at Amarna Therapeutics BV, board member of Recipharm AB, Chromafora AB, Buzzard Pharmaceuticals AB, Flerie Invest AB, Sixera Pharma AB, Kahr Bio Ltd, Provell Pharmaceuticals LLC, among others.

Holdings:

Holds 8 982 639 shares through Flerie Invest AB.

Independent in relation to company and company management: Yes

Independent in relation to primary owners: No

Tomas Kramar Board Member Nanologica AB

Tomas Kramar

Born 1954
Board member since 2020

Member of the remuneration committee

Education and training:

Master of Science in Chemical Engineering from Lund University of Technology

Main experience:

40 years’ experience of leading large companies, as well as start-ups. Most recently CEO in Sweden of Siemens Healthineers and before that CEO in Sweden for Siemens Healthcare Diagnostics. Tomas has also been a board member and chairman of the board in large and small companies.                                                                                      

Other board appointments:

Chairman of the board of T.M. Kramar Group AB and Percy Falk Cancerstiftelse. Board member of Corsmed AB, Cytacoat AB, Gentian A/S and Lundonia Biotech AB.

Holdings:

Holds 20,000 shares and 55,000 options.

Independent in relation to company and company management: Yes

Independent in relation to primary owners: Yes

Anders Rabbe Board Member Nanologica AB

Anders Rabbe

Born 1970
Board member since 2020

Member of the remuneration committee

Education and training:

Bachelor of Science in business administration from Webster University, Genève. 

Main experience:

Anders has been the CEO of several companies within the biotech and the financial sector. The last 10 years, Anders has held the position as CEO of Isofol Medical AB. Anders currently holds the position of CEO at Wntresearch AB.

Other board appointments:

CEO of Wntresearch AB. Board member of Baricol Bariatrics AB, Investmentaktiebolaget Akkumula AB and Albonja AB.

Holdings:

Holds 10,000 shares and 55,000 options.

Independent in relation to company and company management: Yes

Independent in relation to primary owners: Yes

Lena Torlegård Board Member Nanologica AB

Lena Torlegård

Born 1963
Board member since 2014

Member of the audit committee

EDUCATION AND TRAINING:

Bachelor of Science in business administration from the Stockholm School of Economics

MAIN EXPERIENCE:

More than 20 years of experience as a communications consultant for a large number of companies, including companies in the life science industry. Lena now acts as advisor for financial and corporate communications with several clients in the life science sector through her company Lena Torlegård AB.

OTHER BOARD APPOINTMENTS:

Communications consultant at Lena Torlegård AB. Board member of Annexin Pharma-ceuticals AB, CoDesignSweden AB, IRLAB Therapeutics AB, Integrative Research Laboratories Sweden AB and Synartro AB.

Holdings:

Holds 5,739 shares and 55,000 options.

Independent in relation to company and company management: Yes

Independent in relation to primary owners: Yes